Prices as of 2026/10/30 close
Company comparison · Drugstore Chains
Sundrug is the bigger company, with revenue of ¥842.5B — 1.5x Kusuri no Aoki's ¥566.9B.
Sundrug earns more on each yen of sales, with an operating margin of 5.6% — 0.8 points above Kusuri no Aoki (4.8%).
Revenue growth in the latest results: Kusuri no Aoki +13.0%, Sundrug +5.1%. For next year, Kusuri no Aoki guides for the fastest operating profit growth (+18.1%).
Sundrug pays more on average — ¥5.82M against ¥5.36M at Kusuri no Aoki.
Over the past year the shares moved Kusuri no Aoki +16.5%, Sundrug −11.6%.
Head-to-head wins16 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Sundrug aheadSundrug 3 : Kusuri no Aoki 0
Revenue: Sundrug ¥842.5B / Kusuri no Aoki ¥566.9B
ProfitabilityInvestors
Sundrug aheadSundrug 2 : Kusuri no Aoki 1
Operating margin: Sundrug 5.6% / Kusuri no Aoki 4.8%
GrowthInvestors
Kusuri no Aoki aheadSundrug 1 : Kusuri no Aoki 4
Revenue growth (YoY): Sundrug +5.1% / Kusuri no Aoki +13.0%
Stock & balance sheetInvestors
Kusuri no Aoki aheadSundrug 0 : Kusuri no Aoki 2
Share price, 1 year: Sundrug −11.6% / Kusuri no Aoki +16.5%
Pay & workforceJob seekers
Kusuri no Aoki aheadSundrug 1 : Kusuri no Aoki 2
Average salary: Sundrug ¥5.82M / Kusuri no Aoki ¥5.36M
| Metric | Sundrug | Kusuri no Aoki | Gap |
|---|---|---|---|
| Revenue | ◎¥842.5B | ¥566.9B | 1.5x |
| Operating profit | ◎¥46.8B | ¥27.1B | 1.7x |
| Net income | ◎¥31.4B | ¥17.1B | 1.8x |
| Metric | Sundrug | Kusuri no Aoki | Gap |
|---|---|---|---|
| Operating margin | ◎5.6% | 4.8% | 0.8pt |
| Net margin | ◎3.7% | 3.0% | 0.7pt |
| Revenue per employee | ¥191M | ◎¥9.0B | 47.1x |
| Metric | Sundrug | Kusuri no Aoki | Gap |
|---|---|---|---|
| Revenue growth (YoY) | +5.1% | ◎+13.0% | 7.9pt |
| Operating profit growth (YoY) | ◎+5.2% | +1.9% | 3.3pt |
| Revenue CAGRlast 5 years | +5.8% | ◎+13.1% | 7.3pt |
| Guidance: revenue growthnext FY plan | +4.0% | ◎+12.9% | 8.9pt |
| Guidance: op. profit growthnext FY plan | +4.2% | ◎+18.1% | 13.9pt |
| Metric | Sundrug | Kusuri no Aoki | Gap |
|---|---|---|---|
| Share price, 1 year | −11.6% | ◎+16.5% | 28.1pt |
| Share price, 3 months | −7.6% | ◎+4.3% | 11.9pt |
| Share price (close) | ¥3,616 | ¥4,373 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Sundrug | Kusuri no Aoki | Gap |
|---|---|---|---|
| Average salary | ◎¥5.82M | ¥5.36M | ¥0.45M |
| Starting salary (monthly) | ¥210,000 | ◎¥245,000 | ¥35,000 |
| Average tenure | 8.9 yrs | ◎9.6 yrs | 0.7 |
| Average age | 34.4 | 35.6 | 1.2 |
| Employees | 4,413 | 63 | 70.0x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥3,616-11.6% (1Y)
Sundrug -11.6% over 1Y. Compared: Kusuri no Aoki +16.5%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Sundrug2 segments
Kusuri no Aoki6 segments
AAverage annual salary from the securities filings: Sundrug ¥5.82M, Kusuri no Aoki ¥5.36M. Sundrug pays the most. Averages also depend on staff age and job mix, so check the average age too (Sundrug 34.4, Kusuri no Aoki 35.6).
ARevenue in the latest results: Sundrug ¥842.5B, Kusuri no Aoki ¥566.9B. Sundrug is the bigger company, with revenue of ¥842.5B — 1.5x Kusuri no Aoki's ¥566.9B.
AOperating margins: Sundrug 5.6%, Kusuri no Aoki 4.8%. Sundrug turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Kusuri no Aoki +16.5%, Sundrug −11.6%. Kusuri no Aoki has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
